CHU Bordeaux

Running trials

• Not yet recruiting

  Impact of Artificial Intelligence Algorithm-driven Versus Standard Lifestyle Intervention in Non-Alcoholic Fatty Liver Disease - A Multicenter, Randomized, Open-label, Controlled Trial

  NCT07497750· Source

• Recruiting

  Cohort of Patients With Chronic Myelomonocytic Leukemia

  NCT07512882· Source

• Not yet recruiting

  Long Term Prediction of MASH-related HCC Risk by Proteomics

  NCT07332611· Source

• Not yet recruiting

  Validation of the Proteomic Profiling as a Diagnostic Test for Extra-hepatic Cholangiocarcinoma

  NCT06780553· Source

• Recruiting

  A Study Evaluating the Efficacy and Safety of Divarasib and Pembrolizumab Versus Pembrolizumab and Pemetrexed and Carboplatin or Cisplatin in Participants With Previously Untreated, KRAS G12C-Mutated, Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer

  NCT06793215· Phase 3· Source

• Recruiting

  Acute Reno-Cardiac Action of Dapagliflozin In Advanced Heart Failure Patients on Heart Transplant Waiting List

  NCT06868797· Source

• Recruiting

  Diagnostic Approach for Cholangiocarcinoma Using Liquid Bile Biopsy

  NCT06416397· Source

• Recruiting

  Performance of Lung MRI Combined to Synthetic CT in the Follow-up of Lung Nodules

  NCT06825078· Source

• Recruiting

  Dose Individualization of Chemotherapy in Patients With Gastrointestinal Cancers Lacking a Specific Liver Enzyme

  NCT06475352· Phase 2· Source

• Recruiting

  A Study of NX-5948 in Adults With Relapsed/Refractory B-cell Malignancies

  NCT05131022· Phase 1· Source

• Active, not recruiting

  A Study of Atezolizumab With Lenvatinib or Sorafenib Versus Lenvatinib or Sorafenib Alone in Hepatocellular Carcinoma Previously Treated With Atezolizumab and Bevacizumab

  NCT04770896· Phase 3· Source

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Liver and biliary tract cancer3 recruiting
• Fatty liver disease (MASLD/MASH)2 recruiting
• Lung cancer2 recruiting
• Chronic lymphocytic leukaemia1 recruiting
• Chronic myeloid leukaemia1 recruiting
• Colorectal cancer1 recruiting
• Diffuse large B-cell lymphoma1 recruiting
• Follicular lymphoma1 recruiting
• Heart failure1 recruiting
• Mantle cell lymphoma1 recruiting

Researchers

No researcher is linked here yet.

Closed trials

• Completed

  Ground-Breaking Electroporation-based Intervention for PERSistent Atrial Fibrillation Treatment (BEAT PERS-AF)

  NCT05418725· Source

• Completed

  Placebo-controlled, Proof-of-concept Study to Evaluate the Safety and Efficacy of Lanifibranor Alone and in Combination With SGLT2 Inhibitor EmpaGliflozin in patiEnts With NASH and Type 2 Diabetes Mellitus

  NCT05232071· Phase 2· Source

• Completed

  Ground-Breaking Electroporation-based Intervention for PAROXysmal Atrial Fibrillation Treatment (BEAT PAROX-AF)

  NCT05159492· Source

• Terminated

  Open-Label Surufatinib in European Patients With NET

  NCT04579679· Phase 2· Source

• Terminated

  Epidemiology and Clinical Characteristics of Non-Tuberculous Mycobacteria Infections in Cystic Fibrosis Patients.

  NCT03312075· Source

• Terminated

  A Study of Atezolizumab (Anti-PD-L1 Antibody) as Adjuvant Therapy After Definitive Local Therapy in Patients With High-Risk Locally Advanced Squamous Cell Carcinoma of the Head and Neck

  NCT03452137· Phase 3· Source